Clinical outcomes of the management of basal cell carcinomas in individuals aged 90 years and over - a retrospective cohort study.

IF 3.7 4区 医学 Q1 DERMATOLOGY Clinical and Experimental Dermatology Pub Date : 2024-08-17 DOI:10.1093/ced/llae344
Isabelle Nicholls, Marc Moncrieff, Martyn Patel, Jenny Nobes, Jennifer Garioch
{"title":"Clinical outcomes of the management of basal cell carcinomas in individuals aged 90 years and over - a retrospective cohort study.","authors":"Isabelle Nicholls, Marc Moncrieff, Martyn Patel, Jenny Nobes, Jennifer Garioch","doi":"10.1093/ced/llae344","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A retrospective cohort study was undertaken to examine the management of basal cell carcinoma (BCC) in older patients.</p><p><strong>Objectives: </strong>The aim was to identify subgroups where intervention could be minimised, based on frailty and trends in survival.</p><p><strong>Methods: </strong>All patients aged 90 years and over with histologically confirmed BCC during 2017 and 2018 were included within the study (n = 319).</p><p><strong>Results: </strong>Age was the most significant predictor of survival (HR=1.10 (95% CIs: 1.04-1.17); p=0.001). Maximum threshold analysis identified 93 years as the significant age cutpoint. Median survival was 40 months for ≤93 years and 28 months for >93 years (p=0.002). Patients with dementia had a worse survival than those without (median survival: 25 months versus 35 months, respectively; HR=1.92 (95% CIs: 1.18-3.13); p=0.009). There was a statistically significant difference in survival for patients who received treatment for their BCC (n=294) compared those observed (n=25) (median survival 34 months versus 21 months, respectively; HR= 0.54 (95% CIs: 0.34-0.85); p=0.007). All other comorbidities examined had no influence on survival.</p><p><strong>Conclusions: </strong>This study provides evidence in support of active treatment of BCC in individuals aged ≥90 years, seen in secondary care. Conservative options may be preferable in patients with dementia or those >93 years old.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llae344","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A retrospective cohort study was undertaken to examine the management of basal cell carcinoma (BCC) in older patients.

Objectives: The aim was to identify subgroups where intervention could be minimised, based on frailty and trends in survival.

Methods: All patients aged 90 years and over with histologically confirmed BCC during 2017 and 2018 were included within the study (n = 319).

Results: Age was the most significant predictor of survival (HR=1.10 (95% CIs: 1.04-1.17); p=0.001). Maximum threshold analysis identified 93 years as the significant age cutpoint. Median survival was 40 months for ≤93 years and 28 months for >93 years (p=0.002). Patients with dementia had a worse survival than those without (median survival: 25 months versus 35 months, respectively; HR=1.92 (95% CIs: 1.18-3.13); p=0.009). There was a statistically significant difference in survival for patients who received treatment for their BCC (n=294) compared those observed (n=25) (median survival 34 months versus 21 months, respectively; HR= 0.54 (95% CIs: 0.34-0.85); p=0.007). All other comorbidities examined had no influence on survival.

Conclusions: This study provides evidence in support of active treatment of BCC in individuals aged ≥90 years, seen in secondary care. Conservative options may be preferable in patients with dementia or those >93 years old.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
90 岁及以上老年人基底细胞癌的临床治疗效果 - 一项回顾性队列研究。
背景:我们开展了一项回顾性队列研究,探讨老年基底细胞癌(BCC)的治疗方法:我们开展了一项回顾性队列研究,以检查老年患者基底细胞癌(BCC)的治疗情况:目的:根据虚弱程度和生存趋势,确定可尽量减少干预的亚组:研究纳入了2017年和2018年期间组织学确诊为BCC的所有90岁及以上患者(n = 319):年龄是预测生存率的最重要因素(HR=1.10(95% CIs:1.04-1.17);P=0.001)。最大阈值分析确定 93 岁为重要的年龄切点。≤93岁患者的中位生存期为40个月,大于93岁患者的中位生存期为28个月(P=0.002)。痴呆症患者的生存期比非痴呆症患者更短(中位生存期:分别为25个月和35个月;HR=1.92(95% CIs:1.18-3.13);P=0.009)。接受 BCC 治疗的患者(人数=294)与观察到的患者(人数=25)相比,生存期差异有统计学意义(中位生存期分别为 34 个月和 21 个月;HR=0.54(95% CIs:0.34-0.85);P=0.007)。所有其他合并症对生存期均无影响:这项研究为在二级医疗机构就诊的年龄≥90岁的 BCC 患者提供了积极治疗的支持证据。对于痴呆症患者或年龄大于 93 岁的患者,保守治疗可能更可取。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.20
自引率
2.40%
发文量
389
审稿时长
3-8 weeks
期刊介绍: Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
期刊最新文献
Monoclonal Antibodies for the Management of Cutaneous Lupus Erythematosus: An Update on the Current Treatment Landscape. Online Sourcing of Medications: The patient buying medication from online pharmacies abroad. Successful Treatment of Chronic Spontaneous Urticaria using Tralokinumab: A Case Report. An unusual case of dorsal hand papules and nodules. Pustular annular erythema triggered by Empaglifozin.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1